Full-Time

KOL Engagement Manager

Medtech / Medical device Marketing

Confirmed live in the last 24 hours

Penumbra Inc

Penumbra Inc

1,001-5,000 employees

Develops medical devices for vascular conditions

Compensation Overview

$75k - $110k/yr

+ Competitive Compensation Package + Equity Program

Junior, Mid

Company Historically Provides H1B Sponsorship

Alameda, CA, USA

Category
Healthcare Administration & Support
Physicians & Surgeons
Medical, Clinical & Veterinary
Biology & Biotech
Required Skills
Word/Pages/Docs
Tableau
Salesforce
Marketing
Data Analysis
Excel/Numbers/Sheets
Requirements
  • Bachelor’s degree in Marketing, Business, Communications, or a related field with 1+ years of experience in marketing, preferably in the medical device or healthcare industry, or equivalent combination of education and experience
  • Good knowledge of MS Excel and Analytics software (Tableau, Salesforce, etc.)
  • Strong oral, written and interpersonal communication skills
  • High degree of accuracy and attention to detail
  • Proficiency with Microsoft Word, Excel, PowerPoint, and other standard office tools
  • Ability to coordinate remotely via audio/video conferencing
  • Excellent organizational, time management and prioritization skills
  • Ability to interact with team members and customers (internal and external) in a professional manner
  • Ability to set and maintain project delivery timelines with regular updates to key stakeholders
  • Must be creative, self-motivated, team-oriented, proactive, intuitive, organized, collaborative, and flexible
Responsibilities
  • Assist product marketing teams with creating, updating, and managing marketing literature, sales tools, and educational videos
  • Support the creation of marketing materials, including presentations and digital content
  • Manage marketing content, tools, literature, and presentations
  • Collaborate closely with product marketing teams to identify opportunities for new materials and messaging pull through
  • Translate complex ideas and information into clear, actionable recommendations and findings
  • Assist in the creation and management of event-related materials
  • Analyze marketing performance drivers to shape content creation
  • Develop and share key strategic insights through data analysis and visualization
  • Coordinate with internal teams and customers to ensure the timely delivery of materials
  • Maintain marketing calendars and schedules for the vascular franchise
  • Adhere to the Company’s Quality Management System (QMS) as well as domestic and global quality system regulations, standards, and procedures
  • Understand relevant security, privacy and compliance principles and adhere to the regulations, standards, and procedures that are applicable to the Company
  • Ensure other members of the department follow the QMS, regulations, standards, and procedures
  • Perform other work-related duties as assigned
Desired Qualifications
  • Analytical abilities preferred

Penumbra Inc. specializes in creating medical devices aimed at treating neurovascular and peripheral vascular conditions. Their products include a variety of devices for neuro interventions, such as the Penumbra System and the Penumbra SMART COIL, which are used to address issues like stroke. For peripheral vascular diseases, they offer the Indigo System and related devices. These products are designed to assist healthcare professionals in hospitals and clinics, primarily in Europe and the Americas. Penumbra differentiates itself from competitors by focusing on advanced solutions tailored for specific medical needs and by investing in ongoing research and development to enhance their offerings. The company's goal is to provide effective medical devices that improve patient outcomes in the fields of neurology and vascular surgery.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Alameda, California

Founded

2004

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased AI adoption enhances precision in stroke detection, complementing Penumbra's devices.
  • Telemedicine growth creates opportunities for integrating Penumbra's devices with digital health platforms.
  • Global demand for minimally invasive procedures boosts Penumbra's device market potential.

What critics are saying

  • Emerging competitors in neurovascular and peripheral vascular markets threaten Penumbra's market share.
  • Don Kassing's retirement may lead to a temporary gap in strategic guidance.
  • Expansion in Costa Rica could face operational challenges and increased costs.

What makes Penumbra Inc unique

  • Penumbra specializes in innovative devices for neurovascular and peripheral vascular conditions.
  • The company offers a broad portfolio, including the Penumbra System and Indigo System.
  • Penumbra's focus on thrombectomy positions it as a leader in clot removal technologies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Parental Leave

Paid Vacation

Paid Sick Leave

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
PR Newswire
Apr 3rd, 2025
Penumbra, Inc. Schedules First Quarter 2025 Earnings Release And Conference Call For April 23, 2025

ALAMEDA, Calif., April 3, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2025 after market close on Wednesday, April 23, 2025 at 4:30 PM Eastern Time. A press release with first quarter 2025 financial results will be issued after market close that day.Webcast & Conference Call InformationThe conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 6572573), or the webcast can be accessed on the "Events and Presentations" section under the "Investors" tab of the Company's website at www.penumbrainc.com. The webcast will be available on the Company's website for at least two weeks following the completion of the call.About PenumbraPenumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life

Penumbrainc
Mar 17th, 2025
Latest Data on Penumbra's CAVT Technology to Be Presented at SIR 2025: STRIDE, STRIKE-PE, and More

Latest data on Penumbra's CAVT technology to be presented at SIR 2025: STRIDE, STRIKE-PE, and more.

Neuro News International
Feb 28th, 2025
Penumbra launches Access25 delivery microcatheter designed for brain aneurysm access

Penumbra launches Access25 delivery microcatheter designed for brain aneurysm access.

Penumbrainc
Feb 27th, 2025
Penumbra Launches ACCESS25[TM] Delivery Microcatheter Designed for Aneurysm Access and Delivery of Elevated Clinical Benefits

Penumbra recently launched the ACCESS25 Delivery Microcatheter, a single lumen medical device designed to aid physicians in accessing the neurovasculature for the delivery of Penumbra's advanced .020" coil platform.

PR Newswire
Feb 21st, 2025
Penumbra, Inc. Announces Don Kassing Will Retire From Board Of Directors

ALAMEDA, Calif., Feb. 21, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced today that after 17 years of distinguished service, Don Kassing has notified the company that he will retire from the board of directors effective April 1, 2025. Kassing joined Penumbra's Board of Directors in 2008 and has served as Presiding Director since 2015."We are grateful for Don's many contributions to the board over the years, particularly his wisdom and guidance in complex situations and through our phases of growth," said Adam Elsesser, board chair, president and chief executive officer of Penumbra. "We also thank Don for his steadfast leadership and dedication to helping Penumbra advance our mission of helping more and more people over the years."Mr. Kassing is President Emeritus of San Jose State University